MedTrace Logo

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

NCT04625270 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2025-01-29

No results posted yet for this study

Summary

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Conditions

Interventions

DRUG

avutometinib (VS-6766)

avutometinib (VS-6766) monotherapy

DRUG

avutometinib (VS-6766) and defactinib

avutometinib (VS-6766) and defactinib combination

Sponsors & Collaborators

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • GOG Foundation

    collaborator NETWORK

  • Verastem, Inc.

    lead INDUSTRY

Principal Investigators

  • Susana Banerjee, MBBS,MA,PhD · European Network of Gynaecological Oncological Trial Groups (ENGOT)

  • Rachel Grisham, MD · GOG Foundation

  • MD Verastem · Verastem, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2024-11-15
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • France
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04625270 on ClinicalTrials.gov